[Retracted] Comparison of the Ameliorating Effects of Valsartan and Amlodipine on Vascular Endothelial Dysfunction and Oxidative Stress in Elderly Patients with Type H Hypertension
Table 4
Comparison of changes in serum endothelial function indexes and FMD% between the two groups before and after treatment (x̅ ± s).
Group
Cases
H-FABP (ng/mL)
vWF (%)
NO (μmol/L)
FMD%
NMD%
Baseline value
After 24 weeks of treatment
Baseline value
After 24 weeks of treatment
Baseline value
After 24 weeks of treatment
Baseline value
After 24 weeks of treatment
Baseline value
After 24 weeks of treatment
Valsartan group
40
31.10 ± 5.57
19.25 ± 3.82
187.62 ± 47.31
136.54 ± 28.93
44.73 ± 6.24
32.67 ± 4.10
6.25 ± 1.13
9.46 ± 1.32
13.42 ± 4.38
14.20 ± 3.35
Amlodipine group
42
32.76 ± 6.79
24.53 ± 4.31
200.47 ± 54.96
152.38 ± 39.55
43.91 ± 6.05
37.48 ± 5.39
6.33 ± 1.02
7.28 ± 0.91
12.95 ± 3.10
13.05 ± 3.02
t value
-
1.207
5.860
1.134
2.061
0.604
4.531
0.337
8.743
0.563
1.634
P value
-
0.231
<0.001
0.260
0.043
0.547
<0.001
0.737
<0.001
0.575
0.106
H-FABP, heart fatty acid binding protein; vWF, von Willebrand factor; NO, nitric oxide; FMD, flow-mediated dilation; NMD, nitroglycerin-mediated dilation.
